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Recently, we revealed the importance of follicular helper T cells (TFH) in the pathogenesis of primary Sjo¨gren’s syndrome (pSS).
In the present study, we focused on the site of the inflammation and determined the composition of lymphocyte infiltration in
labial salivary gland (LSG) biopsies with special emphasis on TFH and germinal center B cells. We selected tissue blocks obtained
from ten patients at the time of disease onset. Detection of cell specific markers was performed with immunohistochemical and
immunofluorescence stainings. We evaluated patients’ clinical and laboratory features retrospectively and assessed the relation
between disease course and early histopathological findings. LSG biopsies were graded based on the extension and arrangement
level of periductal inflammatory cell infiltrates. TFH cell markers (CD84, PD-1, and Bcl-6) occurred predominantly in more
organized structures with higher focus scores. The coexpression of CD3 and Bcl-6 markers clearly identified TFH cells close to
Bcl-6+ B cells with the typical formation of germinal centers. Systemic features were developed later in the disease course only in
patients with highly structured infiltrates and the presence of TFH cells. Our observations suggest that the presence of TFH cells in
LSGs at the disease onset may predict a more pronounced clinical course of pSS.
1. Introduction
Primary Sjo¨gren’s syndrome (pSS), also known as autoim-
mune epithelitis, is a common chronic autoimmune disease
characterised by the inflammation of exocrine glands and the
clinical signs of xerostomia and keratoconjunctivitis sicca. A
combination of environmental, genetic, and possibly hormo-
nal factors leads to the dysregulation of the glandular epithe-
lium, mononuclear cell infiltration, and abnormal lympho-
cyte activation and proliferation [1, 2]. Aberrant humoral
autoimmune responses, B cell hyperactivity, and autoanti-
body production are the hallmarks of pSS [3–5].
Follicular helper T (TFH) cells are specialized subsets of
effector T cells that provide essential help to antigen specific
B cells in the secondary lymphoid organs. TFH cells are orig-
inated from naive CD4+ T cells which are activated by
dendritic cells (DCs) in the interfollicular or T cell zones
[6, 7]. As a result of the initial interaction with DCs, primed
CD4+ T cells migrate to the border of T and B cell areas
and become pre-TFH cells. This follicular homing process
is directed by Bcl-6, which coordinates the downregulation
of T cell zone homing C-C chemokine receptor type 7
(CCR7) in parallel with the upregulation of B cell region
homing C-X-C chemokine receptor 5 (CXCR5) [8–12]. At the
border of T and B cell areas, the interaction between pre-TFH
cells and activated B cells is crucial for both the generation
of antibody-producing extrafollicular plasmablasts and the
formation of germinal centers (GCs). In order to enter GCs,
pre-TFH cells require mutual signals from activated B cells
via CD28-CD86, ICOS-ICOSL, CD40L-CD40, programmed
cell death protein-1 (PD-1)-PD-1L, and OX40-OX40L as well
as signaling lymphocytic activation molecule (SLAM) family
members [13–17]. In GCs, the interplay between TFH and
GC B cells is bidirectional; survival signals, completed with
interleukin (IL)-21, are important not only for B cell survival,
proliferation, and differentiation but also for the maturation
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of TFH cells [18, 19]. The upregulation of Bcl-6 in activated
GC B cells supports their survival and extremely high prolif-
eration rate and additionally leads to the activation-induced
cytidine deaminase (AID) mediated somatic hypermutation
(SHM) in the dark zone of GCs [20].Through the subsequent
stimulation of CD40 by TFH cells, centroblasts differentiate
into centrocytes and move to the light zone [21]. Follicular
DCs (FDCs) and TFH cells promote the positive selection and
possible immunoglobulin class-switch recombination (CSR)
of several centrocytes resulting in their differentiation into
high-affinity memory B cells and long-lived plasma cells
[22].
Recent studies highlighted the role of TFH cells in the
pathogenesis of different autoimmune conditions, including
systemic lupus erythematosus, Sjo¨gren’s syndrome, rheuma-
toid arthritis, juvenile dermatomyositis, myasthenia gravis,
and autoimmune thyroid disorders [23–28]. In our previous
work, we demonstrated elevated circulating TFH cell percent-
ages in pSS and revealed the importance of this cell type in
the pathogenesis of the disease [29]. Despite the increased
research activity in this field, the molecular mechanisms and
the function of TFH cells are still not known in detail. In
order to extend the current knowledge, in the present study
we focused on the site of the inflammation and assessed
the composition of lymphocyte infiltration in labial salivary
gland (LSG) biopsies with a special emphasis on the presence
and potential importance of TFH cells at the time of disease
onset.
2. Materials and Methods
2.1. Patients. In the present study, we enrolled ten female
patients (mean age ± SD: 57.2 ± 11.4) with pSS, who had
been diagnosed and followed up regularly in the outpatient
clinic for systemic autoimmune diseases at the Division of
Clinical Immunology, University of Debrecen. The diagnosis
of pSS was established according to the European-American
Consensus Group criteria (AECG) [30]. The diagnosis of
the patients was confirmed with positive LSG biopsy at the
disease onset. None of them had evidence of malignant
lymphoma or showed EGMs at the time of the pathological
sampling. Three individuals, who complained of only mild
sicca symptoms without fulfilling diagnostic criteria, served
as controls for the histological evaluation. All patients under-
went extensive clinical and serological examinations during
the follow-up. Data were obtained retrospectively from their
records which contained detailed information on symptoms,
physical conditions, and laboratory and other findings. Anti-
SSA/Ro and anti-SSB/La autoantibodies were determined by
ELISA techniquewithAUTOSTAT II kits (Hycor Biomedical,
Indianapolis, IN, USA) according to the manufacturer’s
instructions. The titers of serum immunoglobulin (Ig)G,
IgA, and IgM were analyzed by turbidimetric immunoassay
(DIALABGmbH,Neudorf, Austria). At the end of the follow-
up, circulating TFH-like cells were determined by CD4,
CXCR5, ICOS, and PD-1 cell surface molecules and were
assessed using BD FACS Calibur flow cytometer (Becton
Dickinson, Franklin Lakes, NJ), as described previously [29].
Informed written consent was given by patients for their
clinical records and archived biopsy samples to be used in
this investigation. The study has been approved by the local
Ethics Committees (Debrecen, Hungary) in 2012 (Reference
number: IX-R-052/00016-22/2012.). All experiments carried
out were in compliance with the Declaration of Helsinki.
2.2. LSG Samples and Conventional Histological Analysis.
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks
were obtained from the archives of theDepartment of Pathol-
ogy, University of Debrecen, which had been previously
collected for routine diagnostic purposes in years 2001–2010.
Four-𝜇m thick serial sections of LSG tissue specimens were
prepared and stained with haematoxylin-eosin (HE) for con-
ventional histopathological examination. The determination
of focus score (FS) was based on the degree of lymphocytic
infiltration in the whole biopsy. The focus score was defined
as the group of inflammatory cell aggregates containing at
least 50 mononuclear cells per 4mm2 of tissue area. It was
classified as FS = 0: no lymphocytic infiltration; FS = 1: less
than 1 lymphocytic focus per 4mm2; FS = 2: less than 2
lymphocytic foci per 4mm2; FS = 3: two ormore lymphocytic
foci per 4mm2 [31].
2.3. Immunohistochemistry. Immunohistochemical (IHC)
staining was performed on serial sections of tissue blocks
using standard methods [32]. Briefly, 4 𝜇m thick FFPE
sections were deparaffinized, rehydrated on descending





endogenous peroxidase. For antigen retrieval, sections were
heated in boiling citrate buffer (pH 6.0) or Tris/EDTA buffer
(pH 9.0) for 3min using a pressure cooker. After cooling,
the slides were incubated with primary antibodies for 1 hour
at room temperature. The following monoclonal antibodies
were (mAb) used in the procedure: CD4, clone 1F6 mouse
mAb (Novocastra, Leica Biosystems, Nussloch, Germany);
CD5, clone 4C7 mouse mAb (Novocastra); CD20, clone
L26 mouse mAb (Dako, Glostrup, Denmark); CD84, clone
EPR8325 rabbit mAb (Abcam, Cambridge, UK); CD138,
clone MI15 mouse mAb (Dako); PD-1, clone NAT mouse
mAb (Abcam); Bcl-6, clone PG-B6p mouse mAb (Dako).
Biotin-free Envision/HRP (Dako) system as secondary Ab
with very intense purple (VIP) peroxidase substrate (Vector
Laboratories, Peterborough, UK) was used for detection.The
sections were then counterstained with methyl green (Vector
Laboratories). The stained tissue samples were digitalized
using Pannoramic MIDI digital slide-scanner (3D-Histech
Co., Budapest, Hungary) utilizing Zeiss Plan-Apochromat
objective (magnification: 20x/0.8 numerical aperture) and
Hitachi (HV-F22CL) 3CCD progressive scan color camera
(resolution: 0.2325 𝜇m/pixel). Image analysis was performed
by the HistoQuant application of Pannoramic Viewer
software 1.15.2. (3D-Histech). If applicable, at least 4 (ranging
from 2 to 6) lymphocytic foci were selected randomly in
each specimen per patient for analytic measurements and
photodocumentation. Field area (FA; overall field area in
mm2) and mask area (MA; overall mask area in mm2) were
computed by the software. The FA represents the whole
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area of the marked infiltrates, while the MA indicates the
cell-specific marker positive area. The relative MA (rMA)
values were calculated as MA/FA multiplied by 100.
2.4. The Characterization of Periductal Cellular Infiltrates.
The organizational levels of each lymphocytic infiltrate were
graded by IHC staining of serial sections using CD4 and
CD20 cell markers. A small number of distributed perivas-
cular and intraepithelial lymphocytes were graded as (1);
mild lymphocytic aggregates without clear organization of
separate T and B cell zones were defined as grade (2);
more organized lymphoid follicles were classified as grade
(3); aggregates with the highest level of arrangement, which
displayed distinct T and B cell regions, were graded as (4).
The latter organization was also characterised by an extensive
FDC network detected with CD21 marker in the center of the
lymphoid aggregates, whose pattern corresponded to ectopic
GC structures.
2.5. Immunofluorescence Staining. Double immunofluores-
cence (IF) staining for Bcl-6 in combination with CD3 (clone
LN10, mmAb, Novocastra) or CD20 was carried out with
sequential immunostaining, as described previously [32].
Sections were prepared and antigens were unmasked as
detailed above. After 1-hour treatment with anti-Bcl-6 pri-
mary Ab, the slides were incubated using anti-mouse
IgG(Fab)
2
as secondary Ab coupled to polymer-HRP (Dako),
followed by a tetramethylrhodamine- (TMR-) conjugated
tyramide reagent of the fluorescent amplification kit (TSR-
TMR System, Perkin Elmer Life Science, Boston, MA,
USA) to visualize the red nuclear fluorescence. The second
layer of the double IF staining was applied with anti-CD3




isothiocyanate (FITC). Nuclear counterstaining was made
with DAPI (blue fluorescence, Vector Laboratories). Images
were obtained using a Zeiss AXIO Imager Z2 microscope
(Carl Zeiss Microscopy GmbH, Jena, Germany) equipped
with the following objectives: 10x/0.3 NA; 20x/0.5 NA. For
transferring and editing images, Isis software (MetaSystems
Group Inc., Newton, MA, USA) and Adobe Photoshop CS5
version 12.0 were used.
3. Results
3.1. Systemic Characteristics of the Study Population during
the Course of the Disease. The mean age at the time of the
diagnosis was 50.80 ± 10.34 and the total duration of follow-
up was 7.40 ± 3.10 years. We evaluated their clinical and
serological features retrospectively and assessed the relation
between laboratory results, disease course, and the early
histopathological findings. Data of patients enrolled in the
study are detailed in Table 1. We divided patients into two
groups based on their FSs. Three patients formed the group
of pSS with FS = 2 and 7 patients belonged to the group of
pSS with FS = 3. None of the patients had FS < 2. Peripheral
TFH-like cell percentages were tendentiously elevated at the
end of follow-up in patients with higher FS at disease onset
(mean percentages of pSS with FS = 3 versus controls: 0.86%
± 0.38 versus 0.32% ± 0.12, and pSS with FS = 3 versus
pSS with FS = 2: 0.86% ± 0.38 versus 0.33% ± 0.08, resp.).
Importantly, systemic features such as polyarthritis (𝑛 = 3),
Raynaud’s syndrome (𝑛 = 2), lymphadenopathy (𝑛 = 1) and
fibrosis pulmonum (𝑛 = 1), and associated diseases including
primary biliary cirrhosis (𝑛 = 1) or primary sclerosing
cholangitis (𝑛 = 1) developed later in the disease course only
in patients with FS = 3.
3.2. Histological Classification of LSG Biopsies according to
Focus Scoring and Grading of the Inflammatory Infiltrates.
When studying themorphology of LSG specimens in patients
with pSS, we identified different organizational levels of
inflammatory mononuclear cell infiltrates. The whole LSG
specimen was characterized based on the FS, while the
extension and the structural arrangement level of each
periductal cellular infiltrate were graded within the biopsy
section. As displayed in Figure 1(a), four distinct categories
could be identified. In our study, the biopsy samples with
FS = 2 consisted of lymphocytic aggregates only graded as
1 or 2. More organized follicles as grade 3 or 4 were exclu-
sively found in pSS with FS = 3. Grade 4 lymphocytic foci
exhibited features of GCs within secondary lymphoid organs.
Figure 1(b) presents the distributions of the four distin-
guished levels of cellular arrangement in the two groups of
patients. In many cases, biopsy specimens included cellular
aggregates of different kinds of grades, particularly in higher
organizational levels.
3.3. Immunohistochemical Characterization of Infiltrating
Cells according to the Cell-Specific Markers in LSG Biopsies.
In the biopsy samples of patients with FS = 2, we observed
only a mild or moderate degree of periductal lymphocytic
infiltration. In pSSwith FS = 3, the infiltrationswere extensive
and penetrated the ductal epithelia with occasional destruc-
tion of the acini. Furthermore, three patients from pSS group
with FS = 3 also had ectopic GC formation in LSG samples.
Serial immunostainings for the incidence and densities of
inflammatory cell-specific markers within the infiltrates of
the subgroups are demonstrated in Figure 2. As shown, cell
surface markers including CD4, CD5, CD20, CD138, CD84,
and PD-1 were found in both groups, albeit in different
arrangements and densities.
In the aggregates of pSS group with FS = 2, mainly
the T helper cell marker CD4, the pan-T cell and B1 cell
marker CD5, and the pan-B cell marker CD20 were detected,
while the TFH-related markers CD84 and PD-1 were less evi-
dent. Cells characterized by the above-mentioned molecules
showed scattered distribution within the infiltrates. The
CD138+ plasma cells were dispersed throughout the whole
LSG samples and found mostly outside the aggregates.
In pSS group with FS = 3, the distribution of specific cell
markers showed a different pattern along with more orga-
nized structures. CD4+ T cells were predominantly localized
at the periphery of infiltrates. Cells penetrating the ductal
epithelia were also positive for CD4. CD5 were detected
mainly in the T cell regions at the periphery of mononuclear
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Grade 1 Grade 2 Grade 3 Grade 4
Patients
Grading the cellular infiltrates
1 2 NoneNone
3 7 6 3
pSS with FS = 2 [n]
pSS with FS = 3 [n]
(b)
Figure 1: The classification of periductal inflammatory infiltrates with different levels of organization. (a) Immunohistochemical stainings
of FFPE sections from representative examples of LSG sections. For rating the periductal lymphocytic infiltrates, paraffin specimens were
stained for CD4, CD20, and in some cases CD21. We distinguished four different grades. Grade 1 displayed scattered T and B cells around the
ducts. Grades 2 and 3 showedmild andmore organized lymphocytic aggregates. Grade 4 indicated a highly organized structure with extensive
FDC network in the center. The magnification of digitalized slides is 10x. Scale bar 200 𝜇m. (b) Distribution of different organizational levels
in patients with pSS. 𝑛: number of biopsy specimens contained at the stage of organization.
cell infiltrates and only a few cells in the B cell area were
positive for it. The CD20+ B cells were principally situated at
the central region of lymphoid follicles. Similar to pSS group
with FS = 2, CD138+ plasma cells were also displayed as a
scattered distribution outside the infiltrates; however, some
of them were observed at the border of B cell zone as well.
The expression of CD84 cell surface molecule was diffused
throughout the inflammatory infiltrate but accumulated at
the inner area. In addition, the expression of PD-1 was solely
found in the location of CD20+ B cells. Bcl-6+ cells were
detected exclusively in pSS with FS = 3. After analysing the
pSS group with FS = 3, intragroup variances were discovered;
at grade 4 organization level Bcl-6+ cells were clustered in
the central region and expressed with higher intensity, while
in grade 3 aggregates Bcl-6+ cells were scattered and showed
much lower expression (data not shown).
Digitalized slide imaging allowed us to make numerical
comparisons for marker expressions between the two groups.
117 slides were digitalized in total, and the studied proteins
were analyzed in randomly selected lymphocytic aggregates.
The average size of the aggregates in pSS with FS = 3 was
larger than those in pSS with FS = 2 [0.3114mm2 (0.095–
0.642) versus 0.1927mm2 (0.058–0.566), resp.]. As shown in
Figure 3, distribution of the expression of cell-specific
molecules varied according to the focus scores of biopsy
samples. The expression of markers which participate in the
TFH-B cell interaction were tendentiously higher in pSS with
FS = 3.
3.4. Double Immunofluorescence for the Demonstration of
T
𝐹𝐻
-Related Bcl-6 with Possible T or B Cell Coexpressions in
Autoreactive Lymphocytes of LSG Biopsies. The last question
of this study was whether Bcl-6 expression was limited to
CD20+ B cell infiltrates of LSG or whether it could be demon-
strated in CD3+ T cells as well. To prove that CD3+Bcl-6+
T cells were involved in the formation of GC-like structures
in LSG, we stained sections by double IF for Bcl-6 and CD3
or CD20 expressions. Figure 4(a) shows the double labeling
of CD3 pan-T cell marker with the transcription factor Bcl-
6 in lesional lymphocytes, indicating that a few T cells in
the infiltrates were positive for Bcl-6. The coexpression of
the two markers clearly identified TFH cells. Bcl-6
+ B cells
with the typical formation of conventional GCs have also
been detected in the central area of the lymphoid follicle
demonstrated in Figure 4(b).
4. Discussion
Obtaining LSG biopsy is part of the routine diagnosis pro-
cedures in pSS according to the AECG, and it provides an
excellent opportunity to reveal the severity of autoimmune
inflammatory processes in the early stage of the disease
[33, 34]. Previous studies revealed the presence of T and
B cells with fewer macrophages and DCs in LSG of pSS
patients [35–37]. The distribution of B cells, DCs, and FDCs
correlates positively with the severity of inflammation [38].
Additionally, Foxp3+ cells and IL-17 and IL-21-producing cells
were also detected in the infiltrates of LSG tissues [39–41]. In
a recent study, Kang et al. demonstrated the coexpression of
IL-21 and CXCR5 in LSG infiltrates which raised the question
about the presence of TFH cells [40]. Maehara et al. focused
on infiltrating T lymphocyte subsets and described that the
expression of T helper 2 and certain TFH-related molecules
was associated with robust lymphocytic accumulation and










Control pSS with FS = 2 pSS with FS = 3
Figure 2: Immunohistochemical analysis of the division of T, B, and plasma cell markers with a special emphasis on TFH-related molecules
in pSS with FS = 2 and pSS with FS = 3. Serial immunostainings of grade 2 and grade 4 aggregates show CD4+ T helper cells, CD5+ T and B1
cells, CD20+ B cells, and CD138+ plasma cells and markers which play a role in the TFH-B cell interaction, namely, CD84, PD-1, and Bcl-6.
The magnification of digitalized slides is 10x. Scale bar 200 𝜇m.
ectopic GC formation [42]. Moreover, Gong et al. recently
demonstrated the ability of epithelial cells to induce the
differentiation of TFH cells in salivary glands [43]. However,
before our present investigations, TFH cells were not studied
in glandular lymphocytic infiltrates with different organiza-
tional levels.
In our study, we classified LSG specimens according to the
severity of inflammatory cell infiltrates not only with focus
scoring but also with grading of the lymphoid aggregates. To
determine the FS and the grades of aggregates, we examined
the entire tissue section.We observed that the biopsy samples
contained different grades ofmononuclear cell infiltrates, and
the periductal lymphoid structures showed a higher level of
organization in pSS group with FS = 3 than in pSS group with
FS = 2.
Ectopic GC structures with peripheral positioned T cells,
centrally localized B cell area, and a reticular pattern of
FDC network were only observed in FS = 3 with grade 4
aggregates. When examining the expression of TFH-related
molecules, such as CD84, PD-1, and Bcl-6 in the infiltrates,
we found a pronounced expression in pSS with FS = 3.
CD84, which is a member of SLAM family, is responsible
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Figure 3: Plots indicating the distribution of T, B, and plasma cell markers with a special emphasis on TFH-related molecules in the
inflammatory infiltrates in the two subgroups. Measurements were performed on digitalized slides with the HistoQuant module of
Pannoramic Viewer software. The relative mask area is indicated in case of each marker that is presented on Figure 2. MA: overall mask
area in mm2-summed area of each detected object in each layer; FA: overall field area in mm2; rMA: (MA/FA) ∗ 100, relative mask (object)
area in %. Horizontal lines represent the mean value of the group.
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Figure 4: Immunofluorescence demonstration of the coexpression of CD3/CD20 and TFH-related molecule Bcl-6 in LSG biopsy. Double
immunofluorescence stainings of LSG biopsy sections from pSS patients with Bcl-6 plus CD3 (a) and Bcl-6 plus CD20 (b). Boxed areas
indicate the localization of the zoomed-in images in the right, in the same order (from top to bottom). The representative images were made
from a biopsy specimen that belonged to the pSS group with FS = 3. Objectives used: 10x/0.3 NA; 20x/0.5 NA.
for the maintenance of stable T-B conjugates to achieve a
complete interaction and helper function by TFH cells [44].
PD-1 receptor, which regulates the selection and survival of B
cells in the GCs, is also an important phenotypic determinant
of TFH cells [45]. Marked Bcl-6 expression was detected
only in grade 4 aggregates with the colocalization of B cell
zone. In grade 3 infiltrates, its expression was significantly
weaker. Bcl-6 expression could not be demonstrated in lower
grades of aggregates at all. It is known that Bcl-6 is specially
expressed by GC B cells during the centroblast phase and
usually, but not consistently, in centrocytes as well [20].
According to experimental studies,BCL6 gene defect resulted

















































Figure 5: Graphical summary of ectopic lymphoid-like structure organization in exocrine tissue of patients with pSS. During the initiation
phase of inflammation, activated T, B, and DC cells accumulate around ductal epithelial structures (a). Inflammatory responses, including
chemokine signals by stromal cells can elicit the formation of more organized lymphoid structures (b) and (c). Aggregates with the highest
organization level display separated T- and B-cell-rich areas with a central network of FDCs, which correspond to ectopic GCs (d). GC
localized TFH cells are characterized by CXCR5, ICOS, PD-1, CD40L, and SLAM family members as CD84, SAP, and IL-21. The interplay
between TFH and GC B cells is essential for the formation and maintenance of ectopic GCs, moreover for the generation of memory B cells
and long-lived plasma cells. DC: dendritic cells; FDC: follicular dendritic cells; GC: germinal center; HEV: high endothelial venule; SAP:
SLAM-associated protein.
in disturbed GCs formation, with the lack of SHM and CSR,
which highlights the role of Bcl-6 in GC responses [46].
Human studies also demonstrated the requirement of Bcl-
6 in the establishment of GCs and found that, in contrast
with aggregates, only real ectopic GCs express detectable
amount of Bcl-6 [47, 48]. For that purpose, we paid a special
attention to the presence and localization of TFH and GC
B cells in the mononuclear cell infiltration. With double IF
staining, we demonstrated that, close to B cell area, a certain
subset of infiltrating T cells expressed both CD3 and Bcl-6
markers, which suggests that the presence of TFH cells was
adjacent to GC B cells in LSG lesions. However, real GC-
like structures with TFH cells were merely found in those
lymphoid follicles that belong to pSS group with FS = 3
and showed more severe inflammatory lesions. Our findings
are in correlation with a previous study which revealed
the presence of AID in lymphocytic aggregates with higher
organizational level in pSS patients [49]. AID is expressed
in GC B cells undergoing SHM and CSR, following the
upregulation of Bcl-6. We summarized the possible role of
TFH cells in lymphoid aggregates in the labial salivary glands
of pSS patients in a graphical figure (Figure 5).
It is important to emphasize that our investigations were
performed on LSG biopsies which were collected at the time
of the diagnosis, when only the initial symptoms developed in
patients.The retrospective evaluation, of both laboratory and
clinical data recorded during the follow-up period, revealed
associations between the formation of GCs with the presence
of TFH cells in LSGs at disease onset and the development
of EGMs and associated diseases during the disease course.
Additionally, patients, who have TFH cells in their salivary
gland infiltrations already at the time of diagnosis, seem to
also have an elevated peripheral TFH cell ratio later in the
disease course. Itmust be considered that the limitation of the
present study is related to its small patient sample; thus, the
correlations between the local presence of TFH cells and the
development of systemic clinical features cannot be justified
statistically. Nevertheless, the present findings are in line with
our earlier observations that the higher proportions of TFH
cells are associated with higher FS in glandular biopsies and
the presence of extraglandular manifestations [29].
5. Conclusion
In the present study we demonstrated that TFH cell markers,
including CD84, PD-1, and Bcl-6, occur predominantly in
more organized inflammatory cell infiltrates developed in
LSGs with higher focus scores. Our results indicate that
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the presence of TFH cells in LSGs at the time of disease
onset may predict a more pronounced clinical course of
pSS; nevertheless, this observation should be confirmed in a
larger patient population as well. We expect that the further
understanding of molecular and cellular regulation of TFH
cells will provide new potential therapeutic targets in the
treatment of pSS patients with systemic manifestations.
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